Trial CTSU-A011801


The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Other
Randomized: Yes
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Priya Jayachandran, M.D.
Other Trial Staff:  Marissa Aldana, Coordinator, Margarita Carranza, D.M., Kristy Sartor Massopust, Coordinator, America Casillas-Lopez, Coordinator, Apoorva Vishwanath, D.M., Othesia Glasgow, D.M., Kimberly Arieli, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.